Haemophilia B: From molecular diagnosis to gene therapy

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 445-451

  Castaldo, Giuseppe ^a,b   Nardiello, Paola ^b   Bellitti, Fabiana ^a   Santamaria, Rita ^a   Rocino, Angiola ^c   Coppola, Antonio ^a   di Minno, Giovanni ^a   Salvatore, Francesco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c Centro Emofilia e Trombosi   (Italy)

Author keywords

Denaturing HPLC (D HPLC); Factor 9 (F9); Factor IX (FIX); Mutations

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DNA; RETROVIRUS VECTOR;

ADENOVIRUS; BLOOD TRANSFUSION; CHROMOSOME XQ; CHROMOSOME XQ27; COHORT ANALYSIS; DIAGNOSTIC TEST; DISEASE CARRIER; DNA POLYMORPHISM; FEMALE; GENE MAPPING; GENE THERAPY; GENETIC ANALYSIS; GERM LINE; HEMOPHILIA B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; LIFE EXPECTANCY; LINKAGE ANALYSIS; MALE; PARTIAL THROMBOPLASTIN TIME; PARVOVIRUS; PRIORITY JOURNAL; PROTHROMBIN TIME; REPRODUCTION; RETROVIRUS; REVIEW; SYMPTOMATOLOGY; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME LINKAGE; X CHROMOSOME RECESSIVE DISORDER;

FACTOR IX; GENE THERAPY; HEMOPHILIA B; HUMANS;

ADENOVIRIDAE; PARVOVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0038735501     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.067     Document Type: Review

References (55)

1. Rosner F. Hemophilia in the Talmud and Rabbinic writings. Ann Int Med 1969; 70:833-7.
2. Ingram GIC. The history of haemophilia. J Clin Pathol 1976; 29:469-79
3. Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002; 55:127-44.
4. Feng J, Drost JB, Scaringe WA, Liu Q, Sommer SS. Mutations in the factor IX gene (F9) during the past 150 years have relative rates similar to ancient mutations. Hum Mutat 2002; 19:49-57.
5. Bottema CD, Ketterling RP, Li S, Yoon HS, Phillips JA III, Sommer SS. Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as "spacer" elements. Am J Hum Genet 1991; 49:820-38.
6. Ketterling RP, Vielhaber E, Li X, Drost J, Schaid DJ, Kasper CK, et al. Germline origins in the human F9 gene: frequent G:C→A:T mosaicism and increased mutations with advanced maternal age. Hum Genet 1999; 105:629-40.
7. Giannelli F, Anagnostopoulos T, Green PM. Mutation rates in humans. II. Sporadic mutation-specific rates and rate of detrimental human mutations inferred from hemophilia B. Am J Hum Genet 1999; 65:1580-7.
8. Sommer SS, Scaringe WA, Hill KA. Human germline mutation in the factor IX gene. Mut Res 2001; 487:1-17.
9. Chen SW, Pellequer JL, Schved JF, Giansily-Blaizot M. Model of a ternary complex between-activated factor VII, tissue factor and factor IX. Thromb Haemost 2002; 88: 74-82.
10. Tagariello G, Belvini D, Salviato R, Are A, De Biasi E, Goodeve A, et al. Experience of a single Italian center in genetic counseling for hemophilia: from linkage analysis to molecular diagnosis. Haematologica 2000; 85:525-9.
11. Giannelli F, Anson DS, Choo KH, Rees DJ, Winship PR, Ferrari N, et al. Characterisation and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency). Lancet 1984; 1:239-41.
12. Grunebaum L, Cazenave JP, Camerino G, Kloepfer C, Mandel JL, Tolstoshev P, et al. Carrier detection of hemophilia B by using a restriction site polymorphism associated with the coagulation factor IX gene. J Clin Invest 1984; 73: 1491-5.
13. Reiss J, Neufeldt U, Wieland K, Zoll B. Diagnosis of haemophilia B using the polymerase chain reaction. Blut 1990; 60:31-6.
14. Lehesjoki AE, Rasi V, de la Chapelle A. Hemophilia B: diagnostic value of RFLP analysis in 19 of the 20 known Finnish families. Clin Genet 1990; 38:187-97.
15. Caprino D, Acquila M, Mori PG. Carrier detection and prenatal diagnosis of hemophilia B with more advanced techniques. Ann Hematol 1993; 67:289-93.
16. Goodeve AC, Chuansumrit A, Sasanakul W, Isarangkura P, Preston FE, Peake IR. A comparison of the allelic frequencies of ten DNA polymorphisms associated with factor VIII and factor IX genes in Thai and Western European populations. Blood Coagul Fibrinolysis 1994; 5:29-35.
17. Shetty S, Ghosh K, Bhide A, Mohanty D. Carrier detection and prenatal diagnosis in families with haemophilia. Natl Med J India 2001; 14:81-3.
18. De la Salle C, Wu Q, Baas MJ, Hanauer A, Ruan C, Cazeneuve JP. Common intragenic and extragenic polymorphisms of blood coagulation factors VIII and IX are different in Chinese and Caucasian populations. Clin Genet 1990; 38:434-40.
19. Chan VV, Yip B, Tong TM, Chan TP, Lau K, Yam I, et al. Molecular defects in haemophilia B: detection by direct restriction enzyme analysis. Br J Haematol 1991; 791:63-9.
20. Van-de-Water NS, Ridgway D, Ockelford PA. Restriction fragment length polymorphisms associated with the factor VIII and factor IX genes in Polynesians. J Med Genet 1991; 28:171-6.
21. Figueiredo MS, Bowen DJ, Silva Junior WA, Zago MA. Factor IX gene haplotypes in Brazilian blacks and characterization of unusual Dde I alleles. Br J Haematol 1994; 87: 789-96.
22. Tartary M, Vidaud D, Piao Y, Costa JM, Bahnak BR, Fressinaud E, et al. Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis. Br J Haematol 1993; 84:662-9.
23. Attali O, Vinciguerra C, Trzeciak MC, Durin A, Pernod G, Gay V, et al. Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations. Thromb Haemost 1999; 82:1437-42.
24. Aguilar-Martinez P, Romey MC, Schved JF, Gris JC, Demaille J, Claustres M. Factor IX gene mutations causing haemophilia B: comparison of SSC screening versus systematic DNA sequencing and diagnostic applications. Hum Genet 1994; 94:287-90.
25. Poon MC, Anand S, Fraser BM, Hoar DI, Sinclair GD. Hemophilia B carrier determination based on family-specific mutation detection by DNA single-strand conformation analysis. J Lab Clin Med 1993; 122:55-63.
26. Liu J, Xiang H, Liu L. [Study on factor IX gene mutation in 74 haemophilia B patients]. Zhonghua Xue Ye Xue Za Zhi 2001; 22:467-9.
27. Ivaskevicius V, Jurgutis R, Rost S, Muller A, Schmitt C, Wulff K, et al. Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data. Br J Haematol 2001; 112:1062-70.
28. Jaloma-Cruz AR, Scaringe WA, Drost JB, Roberts S, Li X, Barros-Nunez P, et al. Nine independent F9 mutations in the Mexican hemophilia B population: nonrandom recurrences of point mutation events in the human germline. Hum Mutat 2000; 15:116-7.
29. Heit JA, Thorland EC, Ketterling RP, Lind TJ, Daniels TM, Zapata RE, et al. Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in Amerindians is similar to the putative endogenous germline pattern. Hum Mutat 1998; 11:372-6.
30. Walter J, Pabinger-Fasching I, Watzke HH. Six novel and three recurrent mutations in nine Austrian patients with hemophilia B. Thromb Haemost 1994; 72:74-7.
31. Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Factor IX gene sequencing by a simple and sensitive 15-hour procedure for haemophilia B diagnosis: identification of two novel mutations. Br J Haematol 2000; 111:549-51.
32. Klein I, Andrikovics H, Bors A, Nemes L, Tordai A, Varadi A. A haemophilia A and B molecular genetic diagnostic programme in Hungary: a highly informative and cost-effective strategy. Haemophilia 2001; 7:306-12.
33. Le Maréchal C, Audrézet MP, Quéré I, Raguénès O, Lagonné S, Férec C. Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling. Hum Genet 2001; 108:290-8.
34. Ravnik-Glavak M, Atkinson A, Glavac D, Dean M. DHPLC screening of cystic fibrosis gene mutations. Hum Mutat 2002; 19:374-83.
35. Oldenburg J, Ivaskevicius V, Rost S, Fregin A, White K, Holinski-Feder E, et al. Evaluation of DHPLC in the analysis of hemophilia A. J Biochem Biophys Methods 2001; 47:39-51.
36. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: a review. Hum Mutat 2001; 17:439-74.
37. Ellis LA, Taylor GR. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat 2000; 15:556-64.
38. Castaldo G, Nardiello P, Bellitti F, Rocino A, Coppola A, Di Minno G, et al. A novel D-HPLC procedure for factor IX gene scanning. Clin Chem 2003. In press.
39. Oldenburg J, Picard JK, Schwaab R. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77:238-42.
40. Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet 2002; 111:88-95.
41. Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75: 30-5.
42. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continous infusion in haemophilia patients undergoing surgery. Haemophilia 1999; 5:96-100.
43. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, et al. Recombinant human factor IX replacement therapy, prophylaxis, and pharmacokinetics in canine haemophilia B. Blood 1996; 88:2603-10.
44. Adamson S, Charlebois T, O'Connel B, Foster W. Viral safety of recombinant factor IX. Semin Haematol 1998; 35: 22-7.
45. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in haemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98:3600-6.
46. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, et al. Clinical evaluation of recombinant factor IX. Semin Haematol 1998; 35:33-8.
47. Russel KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, et al. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thromb Haemost 2001; 85:445-9.
48. Salooja N, Kemball-Cook G, Tuddenham EG, Dyson J. Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. Br J Haematol 2002; 118:839-42.
49. High KA. Gene therapy: a 2001 perspective. Haemophilia 2001; 7 Suppl 1:23-7.
50. Pasi KJ. Gene therapy for haemophilia. Br J Haematol 2001; 115:744-57.
51. Walsh CE, Chao H. Parvovirus-mediated gene transfer for the haemophilias. Haemophilia 2002; 8 Suppl 2:60-7.
52. Rodriguez MH, Enjolras N, Plantier JL, Rea M, Leboeuf M, Uzan G, et al. Expression of coegulation factor IX in a haematopoietic cell line. Thromb Haemost 2002; 87:366-73.
53. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000; 25:35-41.
54. Schneider H, Adebakin S, Themis M, Cook T, Douar AM, Pavirani A, et al. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. J Gene Med 1999; 1:424-32.
55. Schneider H, Muhle C, Douar AM, Waddington S, Jiang QJ, von der Mark K, etal. Sustained delivery of therapeutic concentrations of human clotting factor IX: a comparision of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4:46-53.